#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
“When we see headlines like this, we need to distinguish between acute cardiovascular events from high-dose intoxication and the actual clinical risk profile of therapeutic cannabis use, which is fundamentally different in dose, frequency, and patient selection. The real conversation with my patients is about individual risk factors, route of administration, and whether cannabis is actually the right tool for their condition compared to alternatives with their own stroke risk.”
💊 Recent epidemiologic data suggesting that recreational drug use, including cannabis, may double stroke risk warrants careful clinical consideration, though the summary provided lacks specificity about study design, effect sizes, and whether findings distinguish between cannabis alone and polysubstance use. The mechanistic pathway from cannabis to acute stroke likely involves sympathomimetic effects and prothrombotic changes, but causality remains difficult to establish given confounding factors such as concurrent tobacco use, cardiovascular risk profiles, and socioeconomic determinants that cluster with recreational drug use. Clinicians should remain alert to stroke risk in younger patients presenting with cannabis use, particularly those with additional vascular risk factors or those using high-potency products, while acknowledging that absolute stroke incidence in cannabis users remains relatively low and population-level attributable risk differs from individual clinical risk. A practical approach involves taking detailed substance use histories during cardiovascular risk assessment, counseling patients—especially those with hypert
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: